Immunocore (NASDAQ:IMCR) Reaches New 1-Year Low – Should You Sell?

Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR – Get Free Report)’s share price reached a new 52-week low during mid-day trading on Tuesday. The company traded as low as $27.31 and last traded at $27.74, with a volume of 259,620 shares changing hands. The stock had previously closed at $28.88.

Analyst Upgrades and Downgrades

Several brokerages recently commented on IMCR. TD Cowen raised shares of Immunocore to a “strong-buy” rating in a research report on Monday, August 24th. BTIG Research restated a “buy” rating on shares of Immunocore in a report on Monday. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Immunocore in a research report on Thursday, October 15th. Wall Street Zen cut Immunocore from a “buy” rating to a “hold” rating in a report on Tuesday, July 28th. Finally, JPMorgan Chase & Co. started coverage on Immunocore in a report on Friday, August 21st. They issued an “overweight” rating and a $50.00 target price on the stock. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, three have assigned a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, Immunocore currently has a consensus rating of “Moderate Buy” and a consensus price target of $52.86.

Read Our Latest Stock Report on IMCR

Immunocore Stock Down 3.7%

The stock has a fifty day moving average price of $30.92 and a 200-day moving average price of $31.61. The firm has a market cap of $1.43 billion, a PE ratio of -42.78 and a beta of 0.82. The company has a debt-to-equity ratio of 0.94, a quick ratio of 4.44 and a current ratio of 4.62.

Immunocore (NASDAQ:IMCR – Get Free Report) last posted its quarterly earnings results on Friday, November 6th. The company reported ($0.28) EPS for the quarter, missing the consensus estimate of ($0.17) by ($0.11). Immunocore had a negative net margin of 7.48% and a negative return on equity of 7.96%. The business had revenue of $102.22 million during the quarter, compared to analysts’ expectations of $152.09 million. Research analysts expect that Immunocore Holdings PLC Sponsored ADR will post -0.20 EPS for the current year.

Hedge Funds Weigh In On Immunocore

Hedge funds have recently made changes to their positions in the business. Marshall Wace LLP lifted its holdings in shares of Immunocore by 4.0% during the 3rd quarter. Marshall Wace LLP now owns 614,728 shares of the company’s stock valued at $18,620,000 after acquiring an additional 23,787 shares in the last quarter. Janus Henderson Group PLC increased its holdings in Immunocore by 30.9% in the 1st quarter. Janus Henderson Group PLC now owns 594,712 shares of the company’s stock valued at $17,919,000 after purchasing an additional 140,308 shares in the last quarter. Braidwell LP acquired a new stake in Immunocore in the 2nd quarter valued at $16,552,000. Renaissance Technologies LLC raised its position in Immunocore by 16.4% in the first quarter. Renaissance Technologies LLC now owns 164,000 shares of the company’s stock valued at $4,945,000 after purchasing an additional 23,100 shares during the period. Finally, HighVista Strategies LLC raised its position in Immunocore by 75.6% in the third quarter. HighVista Strategies LLC now owns 75,840 shares of the company’s stock valued at $2,297,000 after purchasing an additional 32,655 shares during the period. Hedge funds and other institutional investors own 84.50% of the company’s stock.

About Immunocore

(Get Free Report)

Immunocore is a biotechnology company that develops T cell receptor (TCR)-based medicines for cancer and other diseases. Its ImmTAX platform is designed to create therapies that direct the body’s T cells toward targets inside cells, including targets that may be difficult for conventional antibody treatments to reach. The company’s marketed medicine, KIMMTRAK (tebentafusp-tebn), is a TCR-based therapy approved in the United States and other markets for certain patients with unresectable or metastatic uveal melanoma.

Recommended Stories

Receive News & Ratings for Immunocore Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunocore and related companies with MarketBeat.com's FREE daily email newsletter.